Pharma Business: Bridging Therapy Gaps

It’s common in to see many companies launching new businesses with large portfolio with an assumption that something will sell and productivity will get justified

In that pursuit, companies identify high growth therapy segments, plan new divisions in those segments and ask staff to identify product portfolio for the division

The vision and strategy is then developed to justify and make a business case.

Many such divisions fail to take off or get closed over a period of time as the vision and strategy lacks justification

The entire process needs to be done upside down for new businesses to succeed

You need to have 2-3 innovative products at the time of launch which can fill therapy gaps and which have the potential of becoming hero’s of the new business.

It’s not necessary to have these 2-3 innovative products as NCE’s – it can be new dosage form, new indication, new value-added packaging etc

The words vision and strategy should not be used as jargons to impress. It should emerge from the unique offerings which can bridge the therapy gap